Atia Vision

Something is shifting in presbyopia-correcting IOLs. For a long time, the questions around these lenses have been variations on the same theme. How much range? How much compromise? How well do patients adapt? The options have improved, but the tradeoffs have remained part of the conversation. An IOL that doesn't rely on light splitting to achieve range of vision represents a fundamentally different approach. Three years of first-in-human data gives surgeons and the broader ophthalmic community a concrete reason to pay attention to what that difference might mean. The question is no longer whether a non-light-splitting approach is theoretically possible. It is whether the field is ready to move toward it. Learn more: https://lnkd.in/gjjQKRAW #AtiaVision #OmniVu #IOL #CataractSurgery #Ophthalmology #IOLDesign Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.

Most presbyopia-correcting IOLs create a range of vision by splitting or redistributing light. It works for some patients. For others, tradeoffs in glare, halos, and contrast sensitivity become the dominant part of the experience. The OmniVu Modular Shape-Changing IOL from Atia Vision takes a different approach. Rather than splitting light, the investigational dual-optic system is designed to leverage the eye's natural focusing mechanism through a fluid-filled, shape-changing base paired with a fixed front optic. The goal is a continuous range of vision from near through distance while maintaining image quality. Learn more: https://lnkd.in/gjjQKRAW #Ophthalmology #CataractSurgery #Presbyopia #IOL #AtiaVision #OmniVu Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.

Range of vision without compromise has been the goal of IOL innovation for decades. It has also been the part that hasn't been solved. Three years of follow-up from the first-in-human study of the OmniVu Lens System is a step toward changing that. Stable refractive outcomes. Continuous range of vision from far through near. A safety profile that has held across 36 months. The early data exists. That matters. Learn more: https://atiavision.com/ #AtiaVision #OmniVu #IOL #CataractSurgery #Ophthalmology Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.

Cataract surgery is one of the most successful elective procedures in medicine. And yet, for a meaningful number of patients, a secondary procedure becomes part of their long-term journey. Posterior capsule opacification (PCO) is one of the most common long-term sequelae following cataract surgery. It occurs when lens epithelial cells migrate across the posterior capsule after IOL implantation, causing progressive visual haze. For many patients, a secondary YAG laser capsulotomy becomes necessary months or years after their original procedure. What drives PCO formation -- and whether lens design plays a meaningful role in its development -- remains an active area of scientific interest. How a lens interacts with the capsular bag, including whether it fills, compresses, or allows the bag to fibrose over time, is one factor researchers continue to explore. As we close out Cataract Awareness Month, it's a worthwhile reminder that the long-term experience of cataract surgery extends well beyond the day of the procedure. #CataractAwarenessMonth #PCO #IOLInnovation #CataractSurgery #Ophthalmology #AtiaVision

Designing an IOL that works with the eye rather than around it starts with a different question. Instead of redistributing light to achieve range, the investigational OmniVu Modular Shape-Changing IOL is designed to engage the eye's natural focusing mechanism. The goal is to deliver a dynamic range of vision (from near through intermediate for far) while aiming to preserve the image quality patients expect. The approach is different at the platform level. And that difference is what we're studying. Learn more about the design rationale here: https://lnkd.in/gjjQKRAW #CataractAwarenessMonth #IOL #Cataract #AtiaVision #OmniVu Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.

It took bold thinking to change cataract surgery once before. In 1949, Sir Harold Ridley implanted the world's first intraocular lens -- a move so radical at the time that many considered it malpractice. But that willingness to challenge the conventional became the foundation of modern cataract surgery as we know it today. In the decades since, the field has made remarkable strides: ✅ Monofocal IOLs restored distance vision for millions ✅ Multifocal and trifocal designs delivered improved near and intermediate vision ✅ EDOF lenses achieved more continuous range of vision Each generation revealed something new about what patients need and what remains worth pursuing. As we mark Cataract Awareness Month, it's worth reflecting: the history of this field is a history of people who kept asking what more was possible. At Atia Vision, that spirit drives what we're working toward. #CataractAwarenessMonth #IOL #Cataract #AtiaVision

One day until #AECOS. One session you won't want to miss. If you're in Madrid for AECOS (American-European Congress of Ophthalmic Surgery), don't miss William Wiley, MD, presenting "Atia Vision: Accommodating IOL." He takes the stage June 11th at 15:58 in Section 3: Optimizing Optical Outcomes. Moderated by William Link, PhD and José Luis Güell, MD, with a panel including José Alfonso, MD, Magda Michna, PhD, Sylvain Sachot, and Julian Stevens, MD. The session centers on a question that continues to drive innovation in the field: what does the next meaningful leap in IOL platform design actually look like? We hope to see you there. #AtiaVision #AECOS2026 #Cataract #IOL Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.

Madrid is about to have a very interesting conversation about the future of cataract surgery. Atia Vision is heading to AECOS (American-European Congress of Ophthalmic Surgery) annual European meeting, and we're proud to have William Wiley, MD, representing us on June 11th with his presentation, "Atia Vision: Accommodating IOL." Dr. Wiley will be exploring the role a new lens platform design may play in delivering dynamic range of vision, preserving image quality and avoiding refractive drift over time.  As the field continues to ask harder questions about what the next generation of lens design could achieve, this is a session worth being part of. If you're attending AECOS Madrid, we hope you'll stop by. Want to get ahead of the discussion before Madrid? Learn more about what we're building: https://atiavision.com/ #AtiaVision #AECOS2026 #Cataract #IOL Disclaimer: The OmniVu Modular Shape-Changing Intraocular Lens (IOL) is an investigational device and is not approved for commercial distribution in the United States or anywhere in the world.